Sun Pharma expects to close the acquisition on or before 31 July 2026.

Sun Pharma’s Q4FY26 numbers missed on margins but not on confidence. Three brokerages stayed bullish as specialty medicines, ...

Sun Pharmaceutical Industries Ltd on Friday reported a 26.2 per cent year-on-year (YoY) rise in net profit for the March 2026 quarter (Q4 FY26). The country's largest drugmaker posted a profit after ...

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) of women’s health leader Organon. With its $11.75 billion buyout, Sun has ...

Sun Pharmaceutical Industries on Sunday said it agreed to acquire Organon & Co. (OGN) in an all-cash transaction valuing the company at an enterprise value of $11.75 billion, marking one of the ...

Sun Pharmaceutical Industries Ltd. settled claims worth $200 million in an antitrust case in Pennsylvania alleging that the firm, along with others, colluded to fix prices of generic drugs. The units ...

July 14 (Reuters) - India's top drugmaker by revenue Sun Pharma (SUN.NS), opens new tab on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute ...

Organon & Co. OGN said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion. According to the terms of the agreement, ...

A Sun Pharmaceutical Industries researcher at work. Sun Pharma has agreed to acquire Organon, the women’s health drug developer spun out of Merck & Co., for $11.75 billion in a deal intended to ...

Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications ...